Beyond the Scale: Your GLP-1 Medication May Be Doing a Lot More Than You Think
If you've been paying attention to health news lately, you've heard of Ozempic, Wegovy, Mounjaro, and Zepbound. These GLP-1 medications have become famous for one thing: helping people lose weight. But here's where it gets interesting. As researchers watched patients in these trials, they kept noticing bonus benefits that had nothing to do with the number on the scale. Better hearts. Healthier livers. Quieter cravings. Some of these findings were so strong that they've earned official FDA approval, while others are still being tested. As a nurse practitioner who works with these medications, I want to walk you through what the science actually says, because this story changes fast and a lot of headlines get it wrong.
First, a quick definition: "off-label" means a medication is being used for something other than what it was originally approved for. Doctors can legally prescribe medications off-label when the evidence supports it. With GLP-1s, several formerly off-label benefits have now become official indications, while others are still under investigation.
Protecting Your Heart
The big one came from the SELECT trial, published in the New England Journal of Medicine (1). Researchers followed more than 17,600 adults with overweight or obesity and existing heart disease, and found that semaglutide (the medication in Wegovy) cut the risk of heart attack, stroke, and cardiovascular death by 20% compared to placebo. That's remarkable for any medication. In March 2024, the FDA officially approved Wegovy to reduce cardiovascular risk in adults with heart disease and overweight or obesity, making it the first weight loss medication also approved to help prevent life-threatening cardiovascular events (2).
Healing Your Liver
Here's one that surprised even specialists. In the ESSENCE trial, published in the New England Journal of Medicine (3), semaglutide resolved fatty liver disease (now called MASH) in about 63% of patients, compared to 34% on placebo, and improved liver scarring (fibrosis) in roughly 37% of patients. Fatty liver disease affects millions of people and had no good medication answer until recently. Wegovy now carries an FDA-approved indication for non-cirrhotic MASH with moderate to advanced fibrosis, the first GLP-1 to earn it (4). Tirzepatide (the medication in Zepbound) has shown similar promise in its own liver trial, SYNERGY-NASH (5).
Quieting Sleep Apnea
If you snore heavily or wake up exhausted, this one may hit close to home. In the SURMOUNT-OSA trials (6), tirzepatide dramatically reduced the severity of obstructive sleep apnea in patients with obesity, cutting apnea events by roughly 50 to 60%. In December 2024, the FDA approved Zepbound as the first-ever medication for moderate to severe obstructive sleep apnea in adults with obesity (7).
Guarding Your Kidneys
The FLOW trial (8) found that semaglutide reduced the risk of kidney disease progression by 24% in people with type 2 diabetes and chronic kidney disease, and the trial was stopped early because the benefit was so clear. This one isn't an official FDA indication yet, but the evidence is strong enough that many specialists are watching this space closely.
Turning Down the Volume on Cravings
Patients tell me all the time that GLP-1s quiet "food noise," that constant mental chatter about eating. The research is starting to back that up, and it may extend beyond food. A randomized trial in JAMA Psychiatry (9) found semaglutide reduced alcohol consumption in people with alcohol use disorder, and a Lancet trial (10) combining semaglutide with counseling cut heavy drinking days even further. Large observational studies have also linked semaglutide to lower risks of opioid overdose (11) and fewer tobacco-related problems (12). These are early days, and no GLP-1 is approved to treat addiction yet, but the signals are genuinely exciting.
Easing Knee Pain
In a New England Journal of Medicine trial (13), people with obesity and painful knee osteoarthritis who took semaglutide lost about 14% of their body weight and reported significantly less knee pain and better function than the placebo group. Less load on the joints, less inflammation, less pain.
Supporting a Struggling Heart
Heart failure with a preserved ejection fraction is a common, exhausting condition that has long had few good treatments. In the STEP-HFpEF trials (14), semaglutide significantly improved symptoms, exercise capacity, and quality of life in people with obesity-related heart failure. It's another reminder that these medications reach far beyond the scale.
A Possible Cancer Signal
One of the newer areas of research: a large 2026 study in the Annals of Oncology followed about 162,000 adults with obesity and no diabetes and found that GLP-1 users had roughly 41% lower rates of obesity-associated cancers compared with matched controls (15). That's a striking association, but it comes from observational data, which can't prove cause and effect. Prospective trials will need to confirm it before anyone draws firm conclusions.
The Honest Reality Check
Good science also means reporting what didn't work, so here's the balance. Large trials testing semaglutide for Alzheimer's disease (the EVOKE program) did not show benefit, and a major phase 3 trial of exenatide for Parkinson's disease was also negative, even though earlier smaller studies had looked promising. That's how science self-corrects, and it's why I'm careful about the hype. And remember, GLP-1s come with real downsides: nausea and digestive issues are common, they can cause muscle loss along with fat (which is why we emphasize protein and strength training), and they aren't right for everyone. One more caution: the FDA has been actively cracking down on illegally compounded copycat GLP-1 products, so the safe route is always a legitimate prescription with proper medical supervision.
The Bottom Line
What started as diabetes and weight loss medications is turning into one of the most fascinating chapters in modern medicine. Whether these medications could help with your heart, liver, sleep, joints, or cravings depends entirely on your personal health picture, and that's exactly the conversation worth having with a provider who knows you.
Curious whether a GLP-1 medication could be part of your health plan? Book a consultation at Better Off and let's talk about your goals.
References:
- Lincoff, A.M. et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 2023.
- FDA. FDA Approves First Treatment to Reduce Risk of Serious Cardiovascular Problems in Adults with Obesity or Overweight. Press announcement, March 2024.
- Newsome, P.N. et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE). New England Journal of Medicine, 2025.
- FDA. Wegovy prescribing information, MASH indication approved under accelerated approval. Verified via FDA drug label database, 2026.
- Loomba, R. et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis (SYNERGY-NASH). New England Journal of Medicine, 2024.
- Malhotra, A. et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine, 2024.
- FDA. FDA Approves First Medication for Obstructive Sleep Apnea. Press announcement, December 2024.
- Perkovic, V. et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine, 2024.
- Hendershot, C.S. et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 2025.
- Klausen, M.K. et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. The Lancet, 2026.
- Hsu, A.Y. et al. Association of Semaglutide With Risk of Opioid Overdose. JAMA Network Open, 2024.
- Annals of Internal Medicine. Semaglutide and Tobacco Use Disorder Outcomes in Patients with Type 2 Diabetes. Target-trial emulation, 2024.
- Bliddal, H. et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. New England Journal of Medicine, 2024.
- Kosiborod, M.N. et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF). New England Journal of Medicine, 2023.
- Hsu, A.H. et al. GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults. Annals of Oncology, 2026.
Photo credit: Ozempic (semaglutide) injection pen, HualinXMN, Wikimedia Commons, CC BY-SA 4.0.